RSHN (RushNet) Research & Development: $ Mil (TTM As of . 20)


What is RushNet Research & Development?

RushNet RSHN -99.00% Research & Development is $ Mil as of . 20.

Research & Development is the aggregate amount of research and development expenses during the year. RushNet's Research & Development for the three months ended in . 20 was $0.00 Mil. RushNet does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in . 20.

RushNet  (OTCPK:RSHN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

RushNet Research & Development Related Terms

RushNet Research & Development Historical Data

* Premium members only.

The historical data trend for RushNet's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RushNet Research & Development Chart

RushNet Annual Data
Trend
Research & Development

RushNet Quarterly Data
Research & Development

RushNet Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $ Mil mean?
RushNet (RSHN) has a Research & Development of $ Mil as of . 20. Research and development expense is the total cost for research and development activities. View historical data on RushNet and its competitors.
Is RushNet's Research & Development too high?
RushNet's current Research & Development is $ Mil.
How does RushNet's Research & Development compare to MOJO and LBIX?
RushNet's Research & Development of $ Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on RushNet and its competitors. RushNet's current Research & Development is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RushNet stock overvalued right now?
RushNet (RSHN) has a current Research & Development of $ Mil. The current Research & Development is $ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For RushNet (RSHN), the current Research & Development is $ Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RushNet Business Description

Address 8465 Merchants Way, Suite 206, Orange Park, FL, USA, 32222
RushNet Inc through its subsidiary heliosDX, a National Clinical Reference Laboratory offers High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. The firm provides physicians with individualized customer service, as well as fast and accurate reporting of results. The company invests in its infrastructure with the most efficient scientific proven instruments and the latest software for patient and physician satisfaction. It allows heliosDX to provide physicians with fast and accurate reporting meetings. The firm excels in patient and client care through physician-designed panels that aid in testing compliance and reporting education.